madman
Super Moderator
Dr. Neal Shore
Neal Shore discusses EMBARK trial exceptional responders who maintained PSA below 0.2 for approximately three years while recovering testosterone. In the combination arm, 4.7% achieved this response versus roughly 1.4% in enzalutamide and ADT monotherapy arms. Less than 1% never recovered testosterone across arms. Overall survival hazard ratio reached 0.6 for combination versus monotherapy ADT. Dr. Shore recommends shared decision-making between doublet and monotherapy enzalutamide approaches. For enzalutamide monotherapy patients, Dr. Shore uses tamoxifen 10 milligrams every two to three days to prevent breast-related symptoms, successfully treating over 30 patients.
atlanticurologyclinics.com
BIO
Dr. Neal Shore graduated from Duke University and Duke University Medical School. He completed his general surgery/urology residency at New York Hospital-Cornell Medical Center/Memorial Sloan Kettering Cancer Center. He serves as the Medical Director for the Carolina Urologic Research Center.
Dr. Shore has conducted more than 400 clinical trials, focusing mainly on genitourinary oncology, and has authored more than 350 peer-reviewed publications and numerous book chapters. He serves on the Society for Immunotherapy of Cancer (SITC) Guidelines Committee for Bladder Cancer, as well as the boards of the Bladder Cancer Advocacy Network, the APCCC Scientific Steering Committee, Maple Tree Cancer Alliance, Alessa Therapeutics, Photocure, and the Duke Global Health Institute. He is the Chair of both the Prostate Cancer Academy and the Bladder/Kidney Cancer Academy, and was the co-chair of the annual AUA International Prostate Forum for 10 years. He has served/serves on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, JUOP, Everyday Urology Oncology, and World Journal of Urology. He is the Editor-in-Chief of Reviews in Urology. He is a Fellow of the American College of Surgeons and a Certified Physician Investigator.
Neal Shore discusses EMBARK trial exceptional responders who maintained PSA below 0.2 for approximately three years while recovering testosterone. In the combination arm, 4.7% achieved this response versus roughly 1.4% in enzalutamide and ADT monotherapy arms. Less than 1% never recovered testosterone across arms. Overall survival hazard ratio reached 0.6 for combination versus monotherapy ADT. Dr. Shore recommends shared decision-making between doublet and monotherapy enzalutamide approaches. For enzalutamide monotherapy patients, Dr. Shore uses tamoxifen 10 milligrams every two to three days to prevent breast-related symptoms, successfully treating over 30 patients.
Neal Shore, MD, FACS | Atlantic Urology Clinics
Dr. Neal Shore is a urologist with Atlantic Urology Clinics in Myrtle Beach, Murrells Inlet, and Carolina Forest.
atlanticurologyclinics.com
Dr. Neal Shore graduated from Duke University and Duke University Medical School. He completed his general surgery/urology residency at New York Hospital-Cornell Medical Center/Memorial Sloan Kettering Cancer Center. He serves as the Medical Director for the Carolina Urologic Research Center.
Dr. Shore has conducted more than 400 clinical trials, focusing mainly on genitourinary oncology, and has authored more than 350 peer-reviewed publications and numerous book chapters. He serves on the Society for Immunotherapy of Cancer (SITC) Guidelines Committee for Bladder Cancer, as well as the boards of the Bladder Cancer Advocacy Network, the APCCC Scientific Steering Committee, Maple Tree Cancer Alliance, Alessa Therapeutics, Photocure, and the Duke Global Health Institute. He is the Chair of both the Prostate Cancer Academy and the Bladder/Kidney Cancer Academy, and was the co-chair of the annual AUA International Prostate Forum for 10 years. He has served/serves on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, JUOP, Everyday Urology Oncology, and World Journal of Urology. He is the Editor-in-Chief of Reviews in Urology. He is a Fellow of the American College of Surgeons and a Certified Physician Investigator.
